Observational studyOncotarget2016

Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.

Daniele Santini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.